27. Deutscher Krebskongress
Deutsche Krebsgesellschaft e. V.
22. - 26.03.2006, Berlin
Central Nervous System Tumors
Meeting Abstract
(OP256)
[Volltext]
A randomized trial of surgery and radiotherapy versus radiosurgery alone in the treatment of single metastasis to the brain
Muacevic A, Wowra B, Kreth FW, Tonn JC[Volltext]
Meeting Abstract
(OP257)
[Volltext]
The regulatory role of transforming growth factor-ß2 in malignant glioma invasion by modulation of extracellular matrix
Hau P, Arslan F, Dörfelt A, Bosserhoff A, Bogdahn U[Volltext]
Meeting Abstract
(OP258)
[Volltext]
Imatinib (STI 571)/ plus Hydroxyurea: Safety and efficacy in pre-treated, progressive Glioblastoma Multiforme (GBM) patients (pts) – an update on the initial 30 pts
Dresemann G[Volltext]
Meeting Abstract
(OP259)
[Volltext]
Imatinib plus Hydroxyurea in Pretreated Non-Progressive Glioblastoma (GBM) – a Single Center Phase II Study
Dresemann G, Hosius C, Weinkauf B, Nikoloya Z, Letvak L[Volltext]
Meeting Abstract
(OP260)
[Volltext]
Re-irradiation of Recurrent Astrocytomas withFractionated Stereotacic Radiotherapy (FSRT)
Combs S, Thilmann C, Edler L, Debus J, Schulz-Ertner D[Volltext]
Meeting Abstract
(PO261)
[Volltext]
Reverse engineering of extended regulatory networks in human gliomas
Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI[Volltext]
Meeting Abstract
(PO262)
[Volltext]
A high-resolution map of the human glioma genome
Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI[Volltext]
Meeting Abstract
(PO263)
[Volltext]
TGF-beta and metalloproteinases suppress NKG2D ligand surface expression differentially on malignant glioma cells
Eisele G, Wischhusen J, Friese M, Mittelbronn M, Meyermann R, Steinle A, Wick W, Weller M[Volltext]
Meeting Abstract
(PO264)
[Volltext]
Targeted tumor therapy with the compound AP 12009 directed against TGF-b2 in high-grade glioma patients: Results of a phase II study
Hau P, Bogdahn U, Koch D, Pichler J, Mehdorn M, Meixensberger J, Schackert G, Grisold W, Stockhammer G, Schneider T, Weller M, Wassmann H[Volltext]
Meeting Abstract
(PO265)
[Volltext]
Continuous low dose chemotherapy in combination with a COX-II inhibitor as an antiangiogenic approach in patients with glioblastoma multiforme
Tüttenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P[Volltext]
Meeting Abstract
(PO266)
[Volltext]
Identification of regeneration and tolerance factor (RTF) as a novel mediator of glioblastoma-associated immunosuppression
Roth P, Aulwurm S, Meyermann R, Beaman K, Weller M, Wischhusen J[Volltext]
Meeting Abstract
(PO267)
[Volltext]
Intracranial arteries as organs at risk in intensity-modulated radiotherapy for skull base tumors
Nieder C, Grosu AL, Astner S, Busch R, Kneschaurek P, Molls M[Volltext]
Meeting Abstract
(PO268)
[Volltext]
Long-term survivors with glioblastoma multiforme after concurrent Temozolomide (TMZ) and radiotherapy
Micke O, Schäfer U, Schüller P, Willich N[Volltext]
Meeting Abstract
(PO269)
[Volltext]
Bortezomib sensitizes primary human esthesioneuroblastoma cells for TRAIL-induced apoptosis
Koschny R, Holland H, Sykora J, Sprick MR, Haas TL, Ganten TM, Krupp W, Bauer M, Ahnert P, Meixensberger J, Walczak H[Volltext]
Meeting Abstract
(PO270)
[Volltext]
STI571 (Imatinib, Glivec) affects the migratory behavior of human glioma cells in vitro
Möhlenbruch M, Möhlenbruch M, Horn S, Herr M, Schollmeyer A, Perneczky A, Hopf N[Volltext]
Meeting Abstract
(PO271)
[Volltext]
Combined Regimen of Temozolomide and liposomal pegylated Doxorubicin in Glioblastoma – Toxicity and Efficacy
Hau P, Jauch T, Baumgart U, Beier C, Beier D, Gänßbauer S, Glas M, Hirschmann B, Koch H, Wismeth C, Steinbrecher A, Bogdahn U[Volltext]
Meeting Abstract
(PO272)
[Volltext]
Cranial Radiation Therapy Induces Acute Cognitive Impairments in Patients with Brain Tumors Only
Welzel G, Fleckenstein K, Thönnessen D, Schaefer J, Hermann B, Kraus-Tiefenbacher U, Mai S, Wenz F[Volltext]
Meeting Abstract
(PO273)
[Volltext]
Bortezomib sensitizes primary human esthesioneuroblastoma cells for TRAIL-induced apoptosis
Koschny R, Holland H, Sykora J, Sprick MR, Haas TL, Ganten TM, Krupp W, Bauer M, Meixensberger J, Walczak H[Volltext]
Meeting Abstract
(PO274)
[Volltext]
Surviving glioblastoma for more than 5 years: the patients´ perspective
Steinbach J, Blaicher HP, Herrlinger U, Wick W, Nägele T, Meyermann R, Tatagiba M, Bamberg M, Dichgans J, Karnath HO, Weller M[Volltext]
Meeting Abstract
(PO275)
[Volltext]
Therapy of medulloblastoma in adults (NOA 07) – a multicentric, population-based pilot study
Beier D, Bogdahn U, Hau P, Grauer O, Weller M, Kortmann RD, Rutkowski S, Wagner S, Engel C, Pietsch T, Warmuth-Metz M, Hofer S[Volltext]
Meeting Abstract
(PO276)
[Volltext]
Radiochemotherapie bei rezidivierten vorbestrahlten malignen Hirntumoren
Schäfer U, Micke O[Volltext]
Meeting Abstract
(PO277)
[Volltext]
Experimental Models of monocytic infiltration into gliomas
Strik H, Hülper P, Hemmerlein B, Erdlenbruch B, Meier J, Kowalewski A, Gold R, Bähr M[Volltext]
Meeting Abstract
(PO278)
[Volltext]
Postoperative radiotherapy of glioblastoma multiforme: analysis und critical assessment of different predictive factors
Piroth MD, Gagel B, Pinkawa M, Stanzel S, Eble MJ[Volltext]
Meeting Abstract
(PO279)
[Volltext]
Clicinal results and results of quality assurance of intraoperative radiotherapy (IORT) in 72 brain tumor patients: Implications of a "learning curve"
Schüller P, Palkovic S, Schröder J, Schuck A, Micke O, Wassmann H, Willich N[Volltext]
Meeting Abstract
(PO280)
[Volltext]
Neoadjuvant Therapy with Temozolomide and 13-cis-Retinoic Acid in High Grade Glioma – a Phase II-Study
Hau P, Hirschmann B, Jauch T, Baumgart U, Beier C, Beier D, Gänßbauer S, Glas M, Koch H, Wismeth C, Steinbrecher A, Bogdahn U[Volltext]
